Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clinical studies have reported that the predominant route of elimination of meglumine antimoniate is renal glomerular filtration. An interaction due to competition with emtricitabine or tenofovir for active renal transport mechanisms is unlikely. However, renal impairment and sometimes fatal renal failure have been described with meglumine antimoniate treatment. Close monitoring of renal function is warranted.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking